Peregrine Pharmaceuticals Inc (PPHM)

0.42
0.01 1.90
NASDAQ : Health Care
Prev Close 0.41
Open 0.40
Day Low/High 0.39 / 0.42
52 Wk Low/High 0.29 / 1.32
Volume 973.60K
Avg Volume 949.40K
Exchange NASDAQ
Shares Outstanding 242.38M
Market Cap 101.80M
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

National Comprehensive Cancer Network (NCCN) Awards Three Grants For Combination Studies Of Peregrine Pharmaceuticals' Bavituximab In Multiple Cancers

National Comprehensive Cancer Network (NCCN) Awards Three Grants For Combination Studies Of Peregrine Pharmaceuticals' Bavituximab In Multiple Cancers

Peregrine's Novel PS-Targeting Immuno-Oncology (I-O) Agent to be Combined with Immunotherapy and Traditional Cancer Treatments in Studies Focused on Glioblastoma, Head and Neck Cancer and Hepatocellular Carcinoma

Avid Bioservices To Participate In Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit

Avid Bioservices To Participate In Cambridge Healthtech Institute's (CHI) 8th Annual The Bioprocessing Summit

Company Selected for Presentation and Panel Participation; Will Showcase Industry-Leading Contract Manufacturing Capabilities Spanning Early Stage Development to Commercialization

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

In trading on Thursday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 15% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $17.22 on the day. As of last close, PPHMP was trading at a 29.60% discount to its liquidation preference amount.

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 15% Yield Mark

In trading on Wednesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 15% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $17.15 on the day. As of last close, PPHMP was trading at a 29.00% discount to its liquidation preference amount.

Peregrine Pharmaceuticals Announces Formal Commissioning Of New, State-of-the-Art Commercial Manufacturing Facility

Peregrine Pharmaceuticals Announces Formal Commissioning Of New, State-of-the-Art Commercial Manufacturing Facility

-- Facility Being Operated by Avid Bioservices Subsidiary With Capacity to Potentially Generate Additional $40 Million in Annual Revenue --

Peregrine Pharmaceuticals Provides Update On Phase III SUNRISE Trial Of Bavituximab

Peregrine Pharmaceuticals Provides Update On Phase III SUNRISE Trial Of Bavituximab

Conference Call With Management Scheduled for 4:30 p.m. Eastern Time

First Week of October 21st Options Trading For Peregrine Pharmaceuticals (PPHM)

First Week of October 21st Options Trading For Peregrine Pharmaceuticals (PPHM)

Investors in Peregrine Pharmaceuticals Inc. saw new options begin trading this week, for the October 21st expiration.

Peregrine Pharmaceuticals And National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration To Evaluate Novel Cancer Treatment Combinations With Bavituximab

Peregrine Pharmaceuticals And National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration To Evaluate Novel Cancer Treatment Combinations With Bavituximab

NCCN Alliance Includes 26 Leading Cancer Centers and World-Class Thought Leaders on Innovative Cancer Combination Therapies

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 12% Yield Mark

Peregrine Pharmaceuticals' Series E Preferred Stock Shares Cross 12% Yield Mark

In trading on Tuesday, shares of Peregrine Pharmaceuticals Inc.'s 10.50% Series E Convertible Preferred Stock were yielding above the 12% mark based on its quarterly dividend (annualized to $2.625), with shares changing hands as low as $21.59 on the day. As of last close, PPHMP was trading at a 12.40% discount to its liquidation preference amount.